Grufity logo
Grufity logo
BJDX

BJDX - Bluejay Diagnostics, Inc. Stock Price, Fair Value and News

$4.71-0.09 (-1.88%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

BJDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BJDX Price Action

Last 7 days

-8.2%

Last 30 days

187.4%

Last 90 days

154.0%

Trailing 12 Months

-27.7%

BJDX RSI Chart

BJDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BJDX Valuation

Market Cap

4.9M

Price/Earnings (Trailing)

-0.71

Price/Sales (Trailing)

13.22

Price/Free Cashflow

-0.73

BJDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

BJDX Fundamentals

BJDX Revenue

Revenue (TTM)

382.8K

BJDX Earnings

Earnings (TTM)

-6.9M

Earnings Growth (Yr)

-2.94%

Earnings Growth (Qtr)

-34.23%

BJDX Profitability

Return on Equity

-165.1%

Return on Assets

-123.3%

Free Cashflow Yield

-136.08%

BJDX Investor Care

Shares Dilution (1Y)

647.07%

Diluted EPS (TTM)

-6.06

BJDX Alerts

  • 5 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023-293.6K338.2K382.8K
2022-133.0K191.0K249.0K
2021---75.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Bluejay Diagnostics, Inc.

BJDX
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
 CEO
 WEBSITEbluejaydx.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES16

Bluejay Diagnostics, Inc. Frequently Asked Questions

BJDX is the stock ticker symbol of Bluejay Diagnostics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Bluejay Diagnostics, Inc. is 4.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, BJDX's PE ratio (Price to Earnings) is -0.72 and Price to Sales (PS) ratio is 13.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BJDX PE ratio will change depending on the future growth rate expectations of investors.